Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

Hepatitis C virus (HCV) is a major cause of liver diseases including liver cirrhosis and
hepatocellular carcinoma. Approximately 3% of the world population is infected with HCV …

After the development of “classical” tricyclic antidepressants and monoamine oxidase
inhibitors, numerous other classes of antidepressant drugs have been introduced onto the …

As antiepileptic drugs (AEDs) and psychotropic agents are increasingly used in
combination, the possibility of pharmacokinetic interactions between these compounds is …

Antiepileptic drug (AED) interactions are a common problem during epilepsy treatment.
Oxcarbazepine (OCBZ) is a keto homologue of carbamazepine (CBZ) with a completely …

Epilepsy is a common disabling neurological disorder associated with increased rates of
mood disorders especially depression as compared to the general population. Most …

This article provides an overview of the pharmacokinetic drug–drug interactions (DDIs) for
agents prescribed for attention-deficit/hyperactivity disorder (ADHD). Polypharmacy in the …

This review summarizes the major known aspects of the metabolism of second-generation
(iprindole, viloxazine, bupropion, mianserin, maprotiline, and trazodone) and fourth …

Antiseizure medications and drugs for psychiatric diseases are frequently used in
combination. In this context, pharmacokinetic interactions between these drugs may occur …

The combined treatment with anticonvulsant and antidepressant drugs is reported in both
neurologic and psychiatric practice; it is, therefore, evident that the issue of managing such …